FDA Grants Accelerated Approval to Herpes Virus-Based Melanoma Drug

What Happens Next

• →Oncolytic virus therapy companies (e.g., Replimune, Candel Therapeutics) see share price surges of 10-20% as investors reprice the regulatory viability of the viral vector platform following FDA precedent.
• →mRNA flu vaccine approval accelerates consolidation of seasonal vaccine manufacturing away from egg-based production, pressuring legacy manufacturers like Sanofi and CSL Seqirus to accelerate mRNA platform investments.
• →The accelerated approval pathway used for the melanoma drug increases FDA submissions of oncolytic virus candidates, creating a regulatory backlog in the Center for Biologics Evaluation and Research within 12 months.
• →OHSU's HIV clearance results in neonatal animal models trigger increased NIH and PEPFAR funding allocations toward early-intervention antiretroviral protocols for perinatal HIV transmission.

Near-term: Oncolytic virus biotech stocks rally sharply; pharma licensing deals and partnership announcements accelerate around viral vector and mRNA platforms within weeks of the approvals. Long-term: Oncolytic viral therapies become a standard arm in melanoma treatment protocols alongside checkpoint inhibitors; egg-based flu vaccine production declines below 50% of US supply as mRNA platforms dominate; early-intervention antiretroviral regimens reshape global perinatal HIV guidelines.